![]() |
市场调查报告书
商品编码
1764875
欧洲器官保存解决方案市场预测(至 2031 年)- 区域分析 - 按产品、应用、类型和最终用户Europe Organ Preservation Solution Market Forecast to 2031 - Regional Analysis - by Product, Application, Type, and End User |
2023 年欧洲器官保存液市场价值为 86,522.54 千美元,预计到 2031 年将达到 1,59,990.22 千美元;预计 2024 年至 2031 年的复合年增长率为 8.1%。
慢性病盛行率上升推动欧洲器官保存解决方案市场
慢性疾病,无论是先天性的还是后天性的,都会随着时间的推移逐渐损害器官。慢性疾病通常不会自行痊癒,但或许有一些方法可以减缓其造成的伤害。这种损害可能需要数十年才能累积到明显影响患者器官功能或需要医疗干预的程度。慢性肾臟病 (CKD) 是一种常见且可能致命的疾病,全球约有十分之一的人患有此病。脂肪肝和C型肝炎等慢性肝病是导致慢性肝衰竭的常见原因。世界卫生组织 (WHO) 估计,全球约有 5,000 万人感染慢性C型肝炎病毒,每年约有 100 万人新增感染病例。 2022 年,约有 24.2 万人死于C型肝炎,主要原因是肝硬化和肝细胞癌。慢性心臟病,包括冠状动脉疾病和先天性心臟病,可导致进行性心臟衰竭。根据英国心臟基金会发布的《全球心臟与循环系统疾病概况》,先天性心臟病是全球儿童健康中一个快速崛起的问题。全球每110个新生儿中约有1个被诊断出患有先天性心臟病,而婴儿成年后确诊的病例每年可能高达120万例,平均每天3300例(即每26秒就有一例)。因此,随着慢性疾病相关器官移植需求的激增,器官保存解决方案的需求也随之增加。
欧洲器官保存解决方案市场概览
欧洲器官保存解决方案市场细分为德国、法国、英国、西班牙、义大利和欧洲其他地区。预计在预测期内,德国和义大利将在区域市场中占据相当大的市场份额。未来几年,法国、英国和西班牙市场可能会迎来丰厚的利润。器官移植数量的增加、导致器官衰竭的慢性病盛行率的上升以及器官保存解决方案的技术进步,推动了欧洲器官保存解决方案市场的成长。预计德国将成为全球器官保存解决方案市场成长的主要贡献者之一。根据“世界人口老化”,2017年德国总人口中近28.0%为60岁及以上,预计到2050年老龄人口将上升到近37.6%。慢性病的盛行率随着年龄的增长而增加。此外,随着年龄的增长,许多器官开始出现故障或功能障碍,增加了对器官移植程序的需求。因此,随着老年人口的增加,对器官保存解决方案的需求也日益增长。
欧洲器官保存解决方案市场收入及预测(2031年)(千美元)
欧洲器官保存解决方案市场细分
欧洲器官保存解决方案市场按产品、应用、类型、最终用户和国家分类。
根据产品类型,欧洲器官保存液市场分为威斯康辛大学溶液、custodiol HTK、Perfadex、HypoThermosol 等。威斯康辛大学溶液在2023年占据了最大的市场份额。
从应用角度来看,欧洲器官保存液市场细分为静态冷藏、低温机械灌注、常温机械灌注等。静态冷藏领域在2023年占据了最大的市场。
依类型划分,欧洲器官保存液市场分为肾臟、肝臟、肺臟、心臟和其他器官。肾臟器官在2023年占据了最大的市场。
根据最终用户,欧洲器官保存解决方案市场细分为器官移植中心、医院和专科诊所。器官移植中心在2023年占据了最大的市场。
依国家/地区划分,欧洲器官保存液市场分为英国、德国、法国、义大利、西班牙和欧洲其他地区。 2023年,德国占据了欧洲器官保存液市场份额的主导地位。
XVIVO Perfusion、TransMedics、OrganOx Limited、Paragonix Technologies, Inc、Dr. Franz Koehler Chemie GmbH 和 Accord Healthcare 是欧洲器官保存解决方案市场领先的公司。
The Europe organ preservation solution market was valued at US$ 86,522.54 thousand in 2023 and is expected to reach US$ 1,59,990.22 thousand by 2031; it is estimated to register a CAGR of 8.1% from 2024 to 2031.
Increasing Prevalence of Chronic Disease Fuels Europe Organ Preservation Solution Market
Chronic diseases, which may be congenital or acquired, can lead to gradual damage to organs over time. A chronic disease typically does not resolve on its own, but there may be ways to slow down the damage caused by the condition. It may take decades for this damage to build up to the point where it noticeably affects patients' organ function or requires medical intervention. Chronic kidney disease (CKD) is a common and potentially fatal condition that affects approximately 1 in every 10 people worldwide. Chronic liver diseases such as fatty liver disease and hepatitis C are the common causes of chronic liver failure. The World Health Organization (WHO) estimates that ~50 million people are living with chronic hepatitis C virus infection worldwide, with approximately 1.0 million new infections occurring each year. In 2022, ~242,000 people died from hepatitis C, mainly due to cirrhosis and hepatocellular carcinoma. Chronic heart diseases, including coronary artery disease and congenital heart disease, can lead to progressive heart failure. According to the Global Heart & Circulatory Diseases Factsheet by the British Heart Foundation, congenital heart disease is a rapidly emerging problem in child health worldwide. It is diagnosed in approximately 1 in 110 births globally, and the diagnoses later in the lives of babies may reach as high as 1.2 million per year, averaging 3,300 per day (or a diagnosis every 26 seconds). Thus, the demand for organ preservation solutions increases with a surge in the need for availability of chronic disease-related organ transplantation procedures.
Europe Organ Preservation Solution Market Overview
The Europe organ preservation solution market is segmented into Germany, France, the UK, Spain, Italy, and the Rest of Europe. Germany and Italy are expected to account for a significant market share in the regional market during the forecast period. The market in France, the UK, and Spain is likely to experience lucrative opportunities in the coming years. The growing number of organ transplantations, rising prevalence of chronic diseases that lead to organ failure, and technological advancements in organ preservation solutions drive the organ preservation solution market growth in Europe. Germany is expected to be among the major contributors to the growth of the organ preservation solution market in worldwide. As per the "World Population Ageing," nearly 28.0% of the total population of Germany was aged 60 and above in 2017, and the aging population is estimated to rise to nearly 37.6% by 2050. The prevalence of chronic diseases increases with age. Also, with growing age, many organs start to malfunction or become dysfunctional, giving rise to the demand for organ transplantation procedures. Thus, with the rising geriatric population, the demand for organ preservation solutions is growing.
Europe Organ Preservation Solution Market Revenue and Forecast to 2031 (US$ Thousand)
Europe Organ Preservation Solution Market Segmentation
The Europe organ preservation solution market is categorized into product, application, type, end user, and country.
Based on product, the Europe organ preservation solution market is categorized into University of Wisconsin solution, custodiol HTK, Perfadex, HypoThermosol, and others. The University of Wisconsin segment held the largest market share in 2023.
In terms of application, the Europe organ preservation solution market is segmented into static cold storage, hypothermic machine perfusion, normothermic machine perfusion, and others. The static cold storage segment held the largest market share in 2023.
By type, the Europe organ preservation solution market is categorized into kidneys, liver, lungs, heart, and others. The kidneys segment held the largest market share in 2023.
Based on end user, the Europe organ preservation solution market is segmented into organ transplant centers, hospitals, and specialty clinics. The organ transplant centers segment held the largest market share in 2023.
By country, the Europe organ preservation solution market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe organ preservation solution market share in 2023.
XVIVO Perfusion, TransMedics, OrganOx Limited, Paragonix Technologies, Inc, Dr. Franz Koehler Chemie GmbH, and Accord Healthcare, are among the leading companies operating in the Europe organ preservation solution market.